Skip to main content
Father's Day Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

CD47 Antibody Combo Shows Meaningful Activity in Previously Untreated AML

Summary by cancernetwork.com
Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.

2 Articles

The Manila TimesThe Manila Times
Lean Right

Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026

HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that compelling results from its randomized, double-blind,...

·Manila, Philippines (the)
Read Full Article
cancernetwork.comcancernetwork.com

CD47 Antibody Combo Shows Meaningful Activity in Previously Untreated AML

Data from a phase 2 trial support further clinical development of AK117 in previously untreated acute myeloid leukemia.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Manila Times broke the news in Manila, Philippines (the) on Wednesday, June 17, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Hong Kong icon

Hong Kong

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal